Although widely used in Europe, 68Ga PET radiopharmaceuticals have only been used in the US in investigational trials under INDs. With the potential of an approved agent available in the US in the near future, this conference is particularly useful to those who are new to this class of agent and want to hear more about it. A team of experts from around the world present their research and discuss updates in this exciting and evolving field. Presentations on clinical applications and patient advocacy are new to this Congress, providing a unique perspective for attendees.
Thursday, March 12, 2015
Generators, Post-Processing, and Synthesis Modules
Chelators and Labeling Chemistry for Theranostic Isotopes
Theranostic Targeting Vectors
Friday, March 13, 2015
Peptide Receptor Radiotherapy – Status Quo and Where to Go
Targeting Prostate Cancer: Imaging and Therapy
Established and Innovative Applications for Diagnosis and Therapy
Saturday, March 14, 2015
State of the Art Management of NETs – Clinician and Patient Perspectives
Imaging with Gallium – From D to T (Diagnosis to Therapy)
How to Deliver Theranostics
Interested in sponsoring/exhibiting at the 3rd Theranostics World Congress on Gallium and PRRT, taking place March 12-14, 2015 at the Johns Hopkins Thomas B. Turner Auditorium in Baltimore, Maryland?
The purpose of the congress is to continue to educate, promote, and support the application and use of Gallium-68 labelled agents in the diagnosis and management of oncologic diseases and the use of theranostic agents for the treatment of these diseases. Your support of the Congress will help increase your brand exposure, while providing the opportunity to interact with key decision-makers and experts in the field, and support efforts to further the discussion on these important topics.